0000000000985776

AUTHOR

G. Perri

showing 3 related works from this author

Workplace violence among healthcare workers, a multicenter study in Italy

2022

Objectives: The purpose of this study is to assess the prevalence and determinants of workplace violence and the sociodemographic risk factors associated. Study design: This was a multicenter cross-sectional study. Methods: The study was performed using self-compiled Italian version of the World Health Organization's questionnaire on workplace violence online by filling in a Google form. The survey was opened from May 2018 to March 2020 and lasted 5-10 min. Results: The sample consists of 3659 healthcare workers, of which 2525 (69%) are females, 1446 (39.5%) are nurses, and 2029 (55.5%) are health workers from northern Italy. The most frequent age group of the sample is 50-54 years (16.7%).…

Malephysical aggressionHealth PersonnelprevalencePublic Health Environmental and Occupational HealthPhysical aggression Prevalence Risk factor Verbal abuse Workplace violenceGeneral MedicineMiddle AgedAggressionverbal abuseCross-Sectional StudiesItalyrisk factorSurveys and Questionnairesworkplace violenceHumansFemalephysical aggression; prevalence; risk factor; verbal abuse; workplace violenceWorkplace
researchProduct

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

2022

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinua…

Antiseizure medicationFocal seizuresAntiseizure medication; Brivaracetam; Epilepsy; Focal seizures.Antiseizure medication; Brivaracetam; Epilepsy; Focal seizures;EpilepsyNeurologyBrivaracetamSettore MED/26 - NeurologiaNeurology (clinical)Antiseizure medication; Brivaracetam; Epilepsy; Focal seizuresSettore MED/26Settore MED/39 - Neuropsichiatria Infantile
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct